Can CAR-T first movers keep pace in a rapidly evolving marke...
The CAR-T landscape has quickly transformed from a pioneering breakthrough to a highly competitive and evolving market.
Newsletters and Deep Dive digital magazine
The CAR-T landscape has quickly transformed from a pioneering breakthrough to a highly competitive and evolving market.
Access to a stem cell transplant in the US - and the chances of surviving it - depends on social and economic factors, finds a new study.
After a string of trial failures, MSD claims a partial win for Keytruda and Lynparza in advanced epithelial ovarian cancer.
GSK reveals the survival data that it reckons could return BCMA drug Blenrep to the forefront of multiple myeloma treatment.
The results of a phase 2 trial of MSD’s anti-ROR1 ADC zilovertamab vedotin back up the company's decision to start a phase 3 trial in DLBCL.
Editor's Picks
Newsletters and Deep Dive
digital magazine
Editor's Picks